Latest billboard in Iowa, USApushing abortionOn September 12, 2012, Health Canada approved the abortion drug Mifegymiso. The drug, according to Health Canada, “is a combination product containing one mifepristone 200 mg tablet (oral administration) and four misoprostol 200 µg tablets (buccal administration). Mifegymiso was authorized for medical termination of a developing intra-uterine pregnancy with a gestational age up to 49 days as measured from the first day of the Last Menstrual Period (LMP) in a presumed 28-day cycle. Mifepristone belongs to the progesterone receptor antagonist therapeutic class, and blocks the progesterone effect on the uterus myometrium and endometrium, rendering the
